Navigation Links
LANI completes Phase I in Japan and to commence Phase I in UK

Melbourne, Australia — 19 April 2007- Biota Holdings Limited (ASX:BTA) today announced that its long acting neuraminidase inhibitor (LANI), CS8958, an anti-influenza treatment, has:

1. demonstrated effectiveness against the avian flu virus H5N1;
2. completed Phase I studies in Japan; and
3. received ethics approval to commence comparable studies in the UK.

Biota’s partner for LANI, Daiichi-Sankyo, overnight announced that laboratory
studies had confirmed CS8958’s effectiveness against the avian flu virus H5N1 in
addition to its effectiveness against influenza A and B type non-avian viruses.
Daiichi-Sankyo also announced that it has completed a Phase I clinical trial in Japan
on CS8958 and expects to start Phase II studies in October.

The UK studies will extend the safety and pharmacokinetics studies of CS8958 in
man. The double-blinded study will involve up to 40 healthy volunteers using a
single dose, and will trial up to four separate, single dose levels. The study is being
funded as part of a US$5.6 million grant provided by the US National Institutes of
Health. The studies will utilise a newly licensed inhaler designed by Hovione and
complement the studies completed by Daiichi-Sankyo in Japan. The UK studies will
generate data in western subjects and lay the basis for further clinical development
outside Japan.

CS8958 is a long acting neuraminidase inhibitor and offers higher potency, lower
dose and the potential for once only treatment and once weekly prophylactic
protection from influenza. These properties are known consumer advantages over
existing inhaled and oral therapies.

CS8958 and a range of other LANI type compounds are co-owned by Biota and
Daiichi-Sankyo.

Biota CEO, Peter Cook said “These are important milestones in the development of
second
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: LANI completes Phase Japan and commence Phase
(Date:8/27/2015)... CHICAGO , Aug. 27, 2015  Hill-Rom Holdings, ... to a management presentation at the Morgan Stanley Global ... ET. You are invited to listen to ... http://ir.hill-rom.com/events.cfm  or access it directly at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . ... be available one hour after the conclusion of the ...
(Date:8/27/2015)... pharmaceutical and medical device companies and leading law firms will ... on Oct. 20, discussing issues surrounding regulatory compliance, ... Litigation Conferences has announced. To learn more ... The program is co-chaired by Megan Grossman ... Hart Yeary of Dechert LLP. Topics include: ...
(Date:8/27/2015)... , August 27, 2015 ... announced a private investment in public equity (PIPE) deal, ... $28.4 million in Itamar Medical.   Through ... shareholder of Itamar Medical and will work closely with ... According to the investment agreement, Itamar Medical ...
Breaking Medicine Technology:Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5
... May 7, 2012  AssureRx Health, Inc. today announced ... the growing number of children and adults diagnosed ... pharmacogenomic test can assist clinicians with important medication ... individual patients tolerate ADHD medications. ...
...  BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, ... announced the completion of a randomized, controlled trial ... product.  ActiPatch uses pulsed electromagnetic field therapy to ... injured tissue. A double blind, ...
Cached Medicine Technology:AssureRx Health Launches Personalized Medicine Test for ADHD 2AssureRx Health Launches Personalized Medicine Test for ADHD 3BioElectronics' ActiPatch Reduces Muscle Soreness in Runners 2
(Date:8/27/2015)... Yardley, Penn. (PRWEB) , ... August 27, 2015 ... ... engagement solutions, confirmed today that its Krames Patient Education content is ICD-10 ready ... and is ready for the new ICD-10 code sets, which are more targeted ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
(Date:8/27/2015)... and OKLAHOMA CITY, OK (PRWEB) , ... August ... ... Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing ... be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon ... The new facility will be located at US Highway 19 North and Highlands Boulevard, less ... 18, and work on the project is slated to begin in September 2015. ...
(Date:8/27/2015)... Collegedale, Tennessee (PRWEB) , ... August 27, 2015 , ... ... preservatives or high fructose corn syrup, is changing the expectation of how protein bars ... a rich, indulgent taste unlike any other protein bar on the market today. ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
... from having problems paying medical bills, and having bill problems ... medicines, a new study has found. According to a ... Journal of Public Health , after taking age, income and ... the odds of accruing debt related to medical care or ...
... Alan Mozes HealthDay Reporter , THURSDAY, June 16 ... habits of America,s teens, new data from the U.S. Centers ... Not only are high school kids guzzling far too ... CDC research team found. In fact, just one in ...
... pilot study of etanercept for treatment of dermatomyositis found ... the drug were successfully weaned from steroid therapy. These ... further investigate the safety and efficacy of etanercept. Results ... of Neurology , a journal published by Wiley-Blackwell on ...
... new study published today in the journal Child ... a poor "gut sense" of numbers can lead to ... math proficiency. This inaccurate number sense is just one ... led by Dr. Michele Mazzocco of the Kennedy Krieger ...
... UT Southwestern Medical Center scientists are shedding new ... fast-acting antidepressant response in patients with treatment-resistant depression. ... as a fast-acting antidepressant potentially has use in emergency ... very sharp increase that immediately relieves depression," said Dr. ...
... of death across a population has evolved in recent ... heart attack and cancer, the role of behavioral factorsincluding ... the 1990s. More recent research has begun to ... mortality. In the first comprehensive analysis of such studies, ...
Cached Medicine News:Health News:Medical debt occurs despite insurance, UA study shows 2Health News:High School Kids Get Too Many Sugary Drinks, Too Little Exercise: CDC 2Health News:High School Kids Get Too Many Sugary Drinks, Too Little Exercise: CDC 3Health News:Etanercept shows promise for treating dermatomyositis 2Health News:Poor 'gut sense' of numbers contributes to persistent math difficulties 2Health News:Poor 'gut sense' of numbers contributes to persistent math difficulties 3Health News:How many US deaths are caused by poverty, low levels of education and other social factors? 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: